BioCardia, Inc. (NASDAQ:BCDA) Short Interest Update

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a significant growth in short interest in January. As of January 31st, there was short interest totalling 53,700 shares, a growth of 67.3% from the January 15th total of 32,100 shares. Currently, 1.4% of the company’s stock are sold short. Based on an average daily trading volume, of 49,700 shares, the short-interest ratio is presently 1.1 days.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on BCDA shares. Alliance Global Partners raised shares of BioCardia from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 30th. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of BioCardia in a research report on Wednesday, December 18th.

Hedge Funds Weigh In On BioCardia

An institutional investor recently raised its position in BioCardia stock. Geode Capital Management LLC raised its stake in shares of BioCardia, Inc. (NASDAQ:BCDA) by 110.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 30,987 shares of the company’s stock after purchasing an additional 16,251 shares during the quarter. Geode Capital Management LLC owned 0.68% of BioCardia worth $68,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 20.57% of the company’s stock.

BioCardia Price Performance

Shares of BCDA traded up $0.12 during trading hours on Friday, hitting $2.84. The company’s stock had a trading volume of 66,744 shares, compared to its average volume of 53,091. The company has a market cap of $13.01 million, a price-to-earnings ratio of -0.68 and a beta of 1.30. The business has a 50 day simple moving average of $2.26 and a two-hundred day simple moving average of $2.49. BioCardia has a 52-week low of $1.63 and a 52-week high of $8.85.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.